Literature DB >> 25399657

Dual antiplatelet therapy after drug-eluting stents--how long to treat?

Antonio Colombo1, Alaide Chieffo.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 25399657     DOI: 10.1056/NEJMe1413297

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected].

Authors:  Robert W Yeh; Laura Mauri; Dean J Kereiakes
Journal:  J Am Coll Cardiol       Date:  2015-03-03       Impact factor: 24.094

2.  Antiplatelet therapy: risks and benefits of extended DAPT after stenting.

Authors:  Karina Huynh
Journal:  Nat Rev Cardiol       Date:  2014-12-02       Impact factor: 32.419

Review 3.  Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention.

Authors:  Joakim Alfredsson; Matthew T Roe
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.606

4.  Dual antiplatelet therapy duration after the placement of a drug-eluting stent: what are the data?

Authors:  Jad Raffoul; Andrew J P Klein
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-03

5.  Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting.

Authors:  Arun K Thukkani; Kush Agrawal; Lillian Prince; Kyle J Smoot; Alyssa B Dufour; Kelly Cho; David R Gagnon; Galina Sokolovskaya; Samantha Ly; Sara Temiyasathit; David P Faxon; J Michael Gaziano; Scott Kinlay
Journal:  J Am Coll Cardiol       Date:  2015-09-08       Impact factor: 24.094

Review 6.  Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.

Authors:  Khaled M Ziada; Ahmed K Abdel-Latif; Richard Charnigo; David J Moliterno
Journal:  Catheter Cardiovasc Interv       Date:  2015-08-26       Impact factor: 2.692

7.  Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study).

Authors:  Keun Ho Park; Myung Ho Jeong; Young Joon Hong; Youngkeun Ahn; Hyun Kuk Kim; Young Yub Koh; Doo Il Kim; Sang Wook Kim; Weon Kim; Seung Woon Rha; Jay Young Rhew; Jong Seon Park; Hun Sik Park; Jang Ho Bae; Jang Whan Bae; Seok Kyu Oh; Sung Yun Lee; Seung Wook Lee; Jae Hwan Lee; Sang Yeob Lim; Jang Hyun Cho; Kwang Soo Cha; Jai Keon Chae; Seung Ho Hur; Sun Ho Hwang; Jin Yong Hwang
Journal:  Yonsei Med J       Date:  2018-01       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.